Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alterations in EGFR, ALK and KRAS. The success of targeted therapy is limited by drug-tolerant persister cells (DTPs) which withstand and adapt to treatment and comprise the residual disease state that is typical during treatment with clinical targeted therapies. Here, we integrate studies in patient-derived and immunocompetent lung cancer models and clinical specimens obtained from patients on targeted therapy to uncover a focal adhesion kinase (FAK)-YAP signaling axis that promotes residual disease during oncogenic EGFR-, ALK-, and KRAS-targeted therapies. FAK-YAP signaling inhibition combined with the primary targeted therapy suppressed residual drug-tolerant cells and enhanced tumor responses. This study unveils a FAK-YAP signaling module that promotes residual disease in lung cancer and mechanism-based therapeutic strategies to improve tumor response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“Prominent examples of targeted inhibitors used as fi rst-line treatment in NSCLC are Osi-mertinib and Alectinib for advanced EGFR-mutant or ALK fusion-positive cancers, respectively 2,3 .”
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 5×
“Conversely, YAP mayundergo nucleartranslocation in responseto the downregulation of LATS expression or activity through various mechanisms 18,28 .”
InfluentialSelf-citationA Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · cited 1×
“Prominent examples of targeted inhibitors used as fi rst-line treatment in NSCLC are Osi-mertinib and Alectinib for advanced EGFR-mutant or ALK fusion-positive cancers, respectively 2,3 .”
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667
Research works printed but not linked: 36
- Bivona, T. G. & Doebele, R. C. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22, 472–478 (2016). · DOI · Paper page
- Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232–1251.e22 (2020). · DOI · Paper page
- Shen, S., Vagner, S. & Robert, C. Persistent cancer cells: the deadly survivors. Cell 183, 860–874 (2020). · DOI · Paper page
- Feng, X. et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer cell 25, 831–845 (2014). · DOI · Paper page
- Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013). · DOI · Paper page
- Moroishi, T., Hansen, C. G. & Guan, K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 15, 73–79 (2015). · DOI · Paper page
- Das, A., Fischer, R. S., Pan, D. & Waterman, C. M. YAP nuclear localization in the absence of cell-cell contact is mediated by a filamentous actin-dependent, myosin ii- and phospho-yap-independent pathway during extracellular matrix mechanosensing. J. Biol. Chem. 291, 6096–6110 (2016). · DOI · Paper page
- Miyazawa, A. et al. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem Biophys. Res Commun. 495, 2344–2349 (2018). · DOI · Paper page
- Ghasemi, H. et al. Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection. Ann. N. Y Acad. Sci. 1473, 48–61 (2020). · DOI
- Zhao, B., Kim, J., Ye, X., Lai, Z.-C. & Guan, K.-L. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res. 69, 1089–1098 (2009). · DOI · Paper page
- Bell, C. C. & Gilan, O. Principles and mechanisms of non-genetic resistance in cancer. Br. J. Cancer 122, 465–472 (2020). · DOI · Paper page
- Wilson, C. et al. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget 5, 7328–7341 (2014). · DOI · Paper page
- Hsia, D. A. et al. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 160, 753–767 (2003). · DOI · Paper page
- Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharmacol. Therapeutics 146, 132–149 (2015). · DOI · Paper page
- Knezevic, N., Tauseef, M., Thennes, T. & Mehta, D. The G protein betagamma subunit mediates reannealing of adherens junctions to reverse endothelial permeability increase by thrombin. J. Exp. Med. 206, 2761–2777 (2009). · doi:10.1084/jem.20090652
- Moroishi, T. et al. The hippo pathway kinases lats1/2 suppress cancer immunity. Cell 167, 1525–1539.e1517 (2016). · DOI · Paper page
- Meraz, I. M. et al. An improved patient-derived xenograft humanized mouse model for evaluation of lung cancer immune responses. Cancer Immunol. Res. 7, 1267–1279 (2019). · DOI · Paper page
- Aissa, A. F. et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat. Commun. 12, 1628 (2021). · DOI · Paper page
- Hu, C. et al. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci. 108, 1347–1356 (2017). · DOI
- Wang, W. et al. Tankyrase inhibitors target YAP by stabilizing angiomotin family proteins. Cell Rep. 13, 524–532 (2015). · DOI · Paper page
- Lange, A. W. et al. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. J. Mol. Cell Biol. 7, 35–47 (2015). · DOI · Paper page
- LaCanna, R. et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J. Clin. Invest. 129, 2107–2122 (2019). · DOI · Paper page
- Holden, J. K. et al. Small molecule dysregulation of TEAD lipidation induces a dominant-negative inhibition of hippo pathway signaling. Cell Rep. 31, 107809 (2020). · DOI · Paper page
- Yap, T. A. et al. First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein(YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solidtumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. In AACR Annual Meeting (AACR, Orlando, Florida, 2023). · DOI
- Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D. & Frame, M. C. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313–324 (2021). · DOI · Paper page
- van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat. Rev. Cancer 20, 218–232 (2020). · DOI · Paper page
- Janse van Rensburg, H. J. & Yang, X. The roles of the Hippo pathway in cancer metastasis. Cell Signal 28, 1761–1772 (2016). · DOI
- Suzuki, K., Bose, P., Leong-Quong, R. Y. Y., Fujita, D. J. & Riabowol, K. REAP: A two minute cell fractionation method. BMC Res. Notes 3, 294 (2010). · DOI · Paper page
- Feng, S. et al. Improved split fluorescent proteins for endogenous protein labeling. Nat. Commun. 8, 370 (2017). · DOI · Paper page
- Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012). · DOI · Paper page
- Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003). · DOI · Paper page
- Guo, Y., Ding, X., Shen, Y., Lyon, G. J. & Wang, K. SeqMule: automated pipeline for analysis of human exome/genome sequencing data. Sci. Rep. 5, 14283 (2015). · DOI
- Hysenaj, L. et al. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator. bioRxiv https://doi.org/10.1101/2021.06.01.446640 (2021). · DOI
- Haderk, F., Olivas, V. & Bivona, T. G. Immunohistochemistry to study YAP in human tissue samples. Methods Mol. Biol. 1893, 89–95 (2019). · DOI
- Sirota, M. et al. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci. Transl. Med. 3, 96ra77 (2011). · DOI · Paper page
- Le, B. L. et al. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19. Sci. Rep. 11, 12310 (2021). · DOI
Cited by
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Therapeutic targeting of TEAD transcription factors in cancer
Pobbati, A. V., Kumar, R., Rubin, B. P., & Hong, W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.12.005 · Cited by 147
IMPlications of IMP2 in RNA Biology and Disease
Das, J., Busia-Bourdain, O., Khan, K. M., & Wolfe, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062415 · Cited by 3
Metadata
- Authors
- Haderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., Allegakoen, D. V., Guan, J., Shah, K. N., Herrington, K. A., Gbenedio, O. M., Nanjo, S., Majidi, M., Tamaki, W., Pourmoghadam, Y. K., Rotow, J. K., McCoach, C. E., Riess, J. W., Gutkind, J. S., Tang, T. T., Post, L., Huang, B., Santisteban, P., Goodarzi, H., Bandyopadhyay, S., Kuo, C. J., Roose, J. P., Wu, W., Blakely, C. M., Roth, J. A., & Bivona, T. G.
- Venue
- Nature Communications
- Published
- 2024-05-03
- Volume
- 15
- Issue
- 1
- Pages
- 3741-3741
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W4396605932
- Cited by
- 103
- References
- 33
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. https://app.cochat.ai/papers/10.1038/s41467-024-47423-0
- The paper
- Haderk, F., Chou, Y.-T., Cech, L., Fernández-Méndez, C., Yu, J., Olivas, V., Meraz, I. M., Barbosa Rabago, D., Kerr, D. L., Gomez, C., Allegakoen, D. V., Guan, J., Shah, K. N., Herrington, K. A., Gbenedio, O. M., Nanjo, S., Majidi, M., Tamaki, W., Pourmoghadam, Y. K., . . . Bivona, T. G. (2024). Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nature Communications. https://doi.org/10.1038/s41467-024-47423-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.